Hemogenyx Pharmaceuticals PLC Directorate Change (0371L)
December 20 2018 - 1:00AM
UK Regulatory
TIDMHEMO
RNS Number : 0371L
Hemogenyx Pharmaceuticals PLC
20 December 2018
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Directorate Change
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments designed to transform
bone marrow transplantation for the treatment of blood diseases,
announces that Robin Campbell, Non-Executive Director, will step
down from the Board with effect from 5 January 2019.
Dr Campbell became a Director of Hemogenyx in October 2017 and
was Chairman during the Company's listing on the Main Market of the
London Stock Exchange. In April 2018 Robin became Non-Executive
Director.
Sir Marc Feldmann, Executive Chairman of Hemogenyx,
commented:
"I would like to thank Robin for his contribution to the
Company, especially during the listing, and for his support as both
Chairman and Non-Executive Director. We wish him well in his future
endeavors."
The Company expects to announce a replacement Board appointment
in the near future.
Enquiries:
Hemogenyx Pharmaceuticals Plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861 6625
Matthew Johnson, Vadim Alexandre, Dugald J
Carlean
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned US operating
subsidiary, Hemogenyx LLC, located in Brooklyn, New York at its
state-of-the-art research facility.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGGGAGPUPRGMB
(END) Dow Jones Newswires
December 20, 2018 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024